$RZLT 8-K SEC Filings

Filed On	Filing
14 Oct 2026	8-K: Regulation FD Disclosure REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced...
05 Oct 2026	8-K: Regulation FD Disclosure The Agency reiterated its commitment to addressing the unmet need for treatment
24 Sep 2026	8-K: Results of Operations and Financial Condition REDWOOD CITY, Calif., September 24, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), ...
02 Jun 2026	8-K: Regulation FD Disclosure
12 May 2026	8-K: Results of Operations and Financial Condition
04 May 2026	8-K: Regulation FD Disclosure
24 Mar 2026	8-K: Regulation FD Disclosure
12 Feb 2026	8-K: Results of Operations and Financial Condition
07 Jan 2026	8-K: Regulation FD Disclosure
21 Nov 2025	8-K: Submission of Matters to a Vote of Security Holders
12 Nov 2025	8-K: Regulation FD Disclosure
06 Nov 2025	8-K: Results of Operations and Financial Condition
21 Oct 2025	8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
17 Sep 2025	8-K: Results of Operations and Financial Condition
02 Sep 2025	8-K: Regulation FD Disclosure
20 Aug 2025	8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more
18 Jul 2025	8-K: Regulation FD Disclosure
13 Jun 2025	8-K: Unregistered Sales of Equity Securities; Other Events
13 May 2025	8-K: Results of Operations and Financial Condition
28 Apr 2025	8-K: Regulation FD Disclosure

Comments